Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Piaopiao Li, Rahul Patel, Jingchuan Guo, Scott M. Vouri, Lizheng Shi, Vivian Fonseca & Hui Shao. (2021) The diminishing cost-effectiveness of the newer glucose-lowering drug classes in the United States: 2010–2018. Current Medical Research and Opinion 37:11, pages 1875-1880.
Read now
Read now
Dhvani Shah, Nancy A Risebrough, Johnna Perdrizet, Neeraj N Iyer, Cory Gamble & Tam Dang-Tan. (2018) Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective. ClinicoEconomics and Outcomes Research 10, pages 791-803.
Read now
Read now
Won Chan Lee, Yevgeniy Samyshkin, Jakob Langer & James L. Palmer. (2012) Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. Journal of Medical Economics 15:sup2, pages 28-37.
Read now
Read now
Caroline M Apovian. (2011) Management of diabetes across the course of disease: minimizing obesity-associated complications. Diabetes, Metabolic Syndrome and Obesity 4, pages 353-369.
Read now
Read now
Articles from other publishers (10)
Dan Teng, Yuning Gong, Zengrui Wu, Weihua Li, Yun Tang & Guixia Liu. (2021)
In Silico
Prediction of Potential Drug Combinations for Type 2 Diabetes Mellitus by an Integrated Network and Transcriptome Analysis
. ChemMedChem 17:3.
Crossref
Crossref
Dongzhe Hong, Lei Si, Minghuan Jiang, Hui Shao, Wai-kit Ming, Yingnan Zhao, Yan Li & Lizheng Shi. (2019) Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review. PharmacoEconomics.
Crossref
Crossref
Néboa Zozaya, Margarita Capel, Susana Simón & Alfonso Soto-González. (2019) A systematic review of economic evaluations in non-insulin antidiabetic treatments for patients with type 2 diabetes mellitus. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 2019, pages 228424031987657.
Crossref
Crossref
Xinyang Hua, Thomas Wai-Chun Lung, Andrew Palmer, Lei Si, William H. Herman & Philip Clarke. (2016) How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review. PharmacoEconomics 35:3, pages 319-329.
Crossref
Crossref
Stephanie J. Fonda, Claudia Graham, Julie Munakata, Julia M. Powers, David Price & Robert A. Vigersky. (2016) The Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes. Journal of Diabetes Science and Technology 10:4, pages 898-904.
Crossref
Crossref
Patrick M. Zueger, Neil M. Schultz & Todd A. Lee. (2014) Cost Effectiveness of Liraglutide in Type II Diabetes: A Systematic Review. PharmacoEconomics 32:11, pages 1079-1091.
Crossref
Crossref
Carl V. Asche, Stephen E. Hippler & Dean T. Eurich. (2013) Review of Models Used in Economic Analyses of New Oral Treatments for Type 2 Diabetes Mellitus. PharmacoEconomics 32:1, pages 15-27.
Crossref
Crossref
Benjamin Gross. (2012) Clinical Pearls for Initiating and Utilizing Liraglutide in Patients With Type 2 Diabetes. Journal of Pharmacy Practice 26:2, pages 144-150.
Crossref
Crossref
M. Gallo. (2014) Thyroid safety in patients treated with liraglutide. Journal of Endocrinological Investigation 36:2, pages 140-145.
Crossref
Crossref
Caroline M. Perry. (2011) Liraglutide. Drugs 71:17, pages 2347-2373.
Crossref
Crossref